Therapy Acceleration Program

June 28, 2019

X4 Pharmaceuticals, LLS Collaborate to Develop Mavorixafor to Treat Waldenström’s Macroglobulinemia

News

X4 Pharmaceuticals and The Leukemia & Lymphoma Society (LLS) have joined forces to accelerate the development of X4’s lead product candidate, mavorixafor, for the treatment of Waldenström’s macroglobulinemia, a rare ... Read more

November 28, 2018December 1, 2018

Leukemia & Lymphoma Society Funding Next Wave of Blood Cancer Research

News

The Leukemia & Lymphoma Society (LLS) has announced $42 million in new grants for 80 disease research teams globally, in its continuing efforts to invest in comprehensive blood cancer research. More ... Read more

November 14, 2018

Verastem Advances Copiktra for Peripheral T-cell Lymphoma Under LLS Therapy Acceleration Program

News

Aiming to accelerate the development of Copiktra (duvelisib) for treatment of peripheral T-cell lymphoma (PTCL) — an aggressive type of non-Hodgkin’s lymphoma — Verastem has announced a collaboration with the Leukemia & Lymphoma Society (LLS). ... Read more